Contribution to More Patient-Friendly ART Treatment: Efficacy of Continuous Low-Dose GnRH Agonist As the Only Luteal Support-Results of a Prospective, Randomized, Comparative Study

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2015 May 7

PMID 25945092

Citations 15

Authors

Celine Pirard

Ernest Loumaye

Pascale Laurent

Christine Wyns

Affiliations

Soon will be listed here.

Abstract

Background. The aim of this pilot study was to evaluate intranasal buserelin for luteal phase support and compare its efficacy with standard vaginal progesterone in IVF/ICSI antagonist cycles. Methods. This is a prospective, randomized, open, parallel group study. Forty patients underwent ovarian hyperstimulation with human menopausal gonadotropin under pituitary inhibition with gonadotropin-releasing hormone antagonist, while ovulation trigger and luteal support were achieved using intranasal GnRH agonist (group A). Twenty patients had their cycle downregulated with buserelin and stimulated with hMG, while ovulation trigger was achieved using 10,000 IU human chorionic gonadotropin with luteal support by intravaginal progesterone (group B). Results. No difference was observed in estradiol levels. Progesterone levels on day 5 were significantly lower in group A. However, significantly higher levels of luteinizing hormone were observed in group A during the entire luteal phase. Pregnancy rates (31.4% versus 22.2%), implantation rates (22% versus 15.4%), and clinical pregnancy rates (25.7% versus 16.7%) were not statistically different between groups, although a trend towards higher rates was observed in group A. No luteal phase lasting less than 10 days was recorded in either group. Conclusion. Intranasal administration of buserelin is effective for providing luteal phase support in IVF/ICSI antagonist protocols.

Citing Articles

Comparison of luteal support protocols in fresh IVF/ICSI cycles: a network meta-analysis.

Kastora S, Gkova G, Stavridis K, Balachandren N, Kastoras A, Karakatsanis A Sci Rep. 2024; 14(1):14492.

PMID: 38914570 PMC: 11196689. DOI: 10.1038/s41598-024-64804-z.

Effect of luteal-phase GnRH agonist on frozen-thawed embryo transfer during artificial cycles: a randomised clinical pilot study.

Liu Y, Huang K, Chen C, Wen L, Lei M, Guo Y Front Endocrinol (Lausanne). 2023; 14:1098576.

PMID: 37361538 PMC: 10289255. DOI: 10.3389/fendo.2023.1098576.

Comparison of pregnancy rates in antagonist cycles after luteal support with GnRH-agonist versus progesterone: prospective randomized study.

Buhbut E, Nabulsi R, Avigdor G, Ben-Ami I Arch Gynecol Obstet. 2023; 308(1):255-263.

PMID: 37186265 DOI: 10.1007/s00404-023-07017-5.

Luteal Phase in Assisted Reproductive Technology.

Tesarik J, Conde-Lopez C, Galan-Lazaro M, Mendoza-Tesarik R Front Reprod Health. 2022; 2:595183.

PMID: 36304702 PMC: 9580649. DOI: 10.3389/frph.2020.595183.

Single-Dose Versus Multiple-Dose GnRH Agonist for Luteal-Phase Support in Women Undergoing IVF/ICSI Cycles: A Network Meta-Analysis of Randomized Controlled Trials.

Liu Y, Wu Y, Pan Z, Jiang F, Lu Y, Meng Y Front Endocrinol (Lausanne). 2022; 13:802688.

PMID: 35432219 PMC: 9008129. DOI: 10.3389/fendo.2022.802688.

References

van der Linden M, Buckingham K, Farquhar C, Kremer J, Metwally M . Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2011; (10):CD009154. DOI: 10.1002/14651858.CD009154.pub2. View

Castillo J, Dolz M, Bienvenido E, Abad L, Casan E, Bonilla-Musoles F . Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support. Reprod Biomed Online. 2010; 20(2):175-81. DOI: 10.1016/j.rbmo.2009.11.018. View

Oliveira J, Baruffi R, Petersen C, Mauri A, Cavagna M, Franco Jr J . Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis. Reprod Biol Endocrinol. 2010; 8:107. PMC: 2942885. DOI: 10.1186/1477-7827-8-107. View

Raga F, Casan E, Kruessel J, Wen Y, Huang H, Nezhat C . Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol Reprod. 1998; 59(3):661-9. DOI: 10.1095/biolreprod59.3.661. View

Isik A, Caglar G, Sozen E, Akarsu C, Tuncay G, Ozbicer T . Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reprod Biomed Online. 2009; 19(4):472-7. DOI: 10.1016/j.rbmo.2009.04.001. View

Shapiro B, Daneshmand S, Garner F, Aguirre M, Hudson C . Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril. 2011; 95(8):2715-7. DOI: 10.1016/j.fertnstert.2011.03.109. View

Raga F, Casan E, Kruessel J, Wen Y, Bonilla-Musoles F, Polan M . The role of gonadotropin-releasing hormone in murine preimplantation embryonic development. Endocrinology. 1999; 140(8):3705-12. DOI: 10.1210/endo.140.8.6899. View

Humaidan P, Ejdrup Bredkjaer H, Westergaard L, Andersen C . 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril. 2009; 93(3):847-54. DOI: 10.1016/j.fertnstert.2008.12.042. View

Kolibianakis E, Schultze-Mosgau A, Schroer A, VAN Steirteghem A, Devroey P, Diedrich K . A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005; 20(10):2887-92. DOI: 10.1093/humrep/dei150. View

10.

Beckers N, Macklon N, Eijkemans M, Ludwig M, Felberbaum R, Diedrich K . Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro.... J Clin Endocrinol Metab. 2003; 88(9):4186-92. DOI: 10.1210/jc.2002-021953. View

11.

Nam D, Lee S, Kim H, Lee G, Jeong Y, Kim S . The role of gonadotropin-releasing hormone (GnRH) and its receptor in development of porcine preimplantation embryos derived from in vitro fertilization. Theriogenology. 2004; 63(1):190-201. DOI: 10.1016/j.theriogenology.2004.04.004. View

12.

Stewart E . Gonadotropins and the uterus: is there a gonad-independent pathway?. J Soc Gynecol Investig. 2001; 8(6):319-26. View

13.

Kawamura K, Fukuda J, Kumagai J, Shimizu Y, Kodama H, Nakamura A . Gonadotropin-releasing hormone I analog acts as an antiapoptotic factor in mouse blastocysts. Endocrinology. 2005; 146(9):4105-16. DOI: 10.1210/en.2004-1646. View

14.

Yildiz G, Sukur Y, Ates C, Aytac R . The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2014; 182:66-70. DOI: 10.1016/j.ejogrb.2014.08.026. View

15.

Macklon N, Fauser B . Impact of ovarian hyperstimulation on the luteal phase. J Reprod Fertil Suppl. 2000; 55:101-8. View

16.

Pirard C, Donnez J, Loumaye E . GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod. 2006; 21(7):1894-900. DOI: 10.1093/humrep/del072. View

17.

Lambalk C, Homburg R . GnRH agonist for luteal support in IVF? Setting the balance between enthusiasm and caution. Hum Reprod. 2006; 21(10):2580-2. DOI: 10.1093/humrep/del321. View

18.

Humaidan P, Thomsen L, Alsbjerg B . GnRHa trigger and modified luteal support with one bolus of hCG should be used with caution in extreme responder patients. Hum Reprod. 2013; 28(9):2593-4. DOI: 10.1093/humrep/det287. View

19.

Orvieto R . Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help?. Reprod Biomed Online. 2012; 24(6):680-1. DOI: 10.1016/j.rbmo.2012.03.005. View

20.

Pritts E, Atwood A . Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod. 2002; 17(9):2287-99. DOI: 10.1093/humrep/17.9.2287. View